Loading
AZD0486 is an experimental bispecific antibody from AstraZeneca in phase 3 trials for diffuse large B-cell lymphoma, aimed at CD19 and CD3.
AZD0486 (TNB-486) is a bispecific antibody developed by AstraZeneca. Its targets are CD19 and CD3 (the sponsor names CD19 x CD3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07215585 (AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL), in diffuse large B-cell lymphoma. The largest, NCT07215585, plans to enrol 420 participants with primary completion expected 2030-06-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of AZD0486 binds CD19 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD0486" OR ABSTRACT:"AZD0486" OR TITLE:"TNB-486" OR ABSTRACT:"TNB-486") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD0486, not a curated reading list.
Shares CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD3, AstraZeneca and the tag pipeline.
Shares CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD3, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD3, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Diffuse large B-cell lymphoma and the tag pipeline.